People
Gillian Russell has over 15 years of experience counseling pharmaceutical, medical device, and cosmetic clients on a wide range of regulatory, compliance, and enforcement issues, with a focus on regulatory strategies and initiatives for the labeling, promotion and advertising of FDA-regulated products. Gillian frequently serves as legal counsel on Medical/Legal/Regulatory (MLR) committees and medical/scientific review committees and is known for providing practical and actionable advice and solutions. Gillian routinely advises on the full spectrum of promotional and non-promotional communications, including new product launches, direct-to-consumer promotion, social media, influencer marketing, and payer communications.
Gillian graduated from the University of Virginia School of Law, where she served as Executive Editor for the Virginia Environmental Law Journal and as a Hardy Cross Dillard fellow for legal research and writing. Gillian earned her B.A. magna cum laude from Princeton University, where she was a four-year member of the swimming team.
J.D., University of Virginia
B.A., Princeton University, Magna Cum Laude
District of Columbia
New Jersey
Pennsylvania
November 8, 2016
King & Spalding Promotes Eight Counsel in Three Offices
“Industry Update – New FDA Guidance on Social Media,” FX Conferences (September 2014).
“The New Drug Approval Process: New Drug Research and Development,” FDLI Introduction to Drug Law and Regulation, Washington, D.C. (April 2, 2014).
July 12, 2024
FDA Issues Updated Draft Guidance on Addressing Misinformation About Medical Devices and Prescription Drugs
April 25, 2024
FDA Updates Draft Guidance on Promotional Labeling and Advertising Considerations for Biological Reference Products and Biosimilars
December 5, 2023
The Legal 500 Country Comparative Guides: United States Pharmaceutical Advertising
November 8, 2016
King & Spalding Promotes Eight Counsel in Three Offices
“Industry Update – New FDA Guidance on Social Media,” FX Conferences (September 2014).
“The New Drug Approval Process: New Drug Research and Development,” FDLI Introduction to Drug Law and Regulation, Washington, D.C. (April 2, 2014).
July 12, 2024
FDA Issues Updated Draft Guidance on Addressing Misinformation About Medical Devices and Prescription Drugs
April 25, 2024
FDA Updates Draft Guidance on Promotional Labeling and Advertising Considerations for Biological Reference Products and Biosimilars
December 5, 2023
The Legal 500 Country Comparative Guides: United States Pharmaceutical Advertising
November 8, 2016
King & Spalding Promotes Eight Counsel in Three Offices
J.D., University of Virginia
B.A., Princeton University, Magna Cum Laude
District of Columbia
New Jersey
Pennsylvania